ArticleBiochemical and biophysical research communications2009
Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway.
Article in Biochemical and biophysical research communications, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 34 citations in OpenAlex.
- Targeting Stress Erythropoiesis Pathways in Cancer.Frontiers in physiology · 2022Review
- The Role of PI3K/AKT and MAPK Signaling Pathways in Erythropoietin Signalization.International journal of molecular sciences · 2021Review
- Chemokine releasing particle implants for trapping circulating prostate cancer cells.Scientific reports · 2020Article
- How to Steer and Control ERK and the ERK Signaling Cascade Exemplified by Looking at Cardiac Insufficiency.International journal of molecular sciences · 2019Article
- Methylation of the first exon in the erythropoietin receptor gene does not correlate with its mRNA and protein level in cancer cells.BMC genetics · 2019Article
- Article
- Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation.British journal of cancer · 2012Article
- Article
- The effect of erythropoietin on normal and neoplastic cells.Biologics : targets & therapy · 2012Article
- Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2011Review
- Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2.American journal of physiology. Lung cellular and molecular physiology · 2011Article
- Role of erythropoietin receptor signaling in parvovirus B19 replication in human erythroid progenitor cells.Journal of virology · 2010Article
- Erythropoietin receptor response circuits.Current opinion in hematology · 2010Review
- Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial.Stem cells (Dayton, Ohio) · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The role of erythropoietin receptor (EpoR) expression in tumor cells and the potential of EpoR-mediated signaling to contribute to cellular proliferation and invasiveness require further characterization. To determine whether EpoR expression and activation in tumor cells modulates intracellular signal transduction to promote cellular proliferation and migration, we employed a novel experimental model using human breast cancer cells engineered to stably express a constitutively active EpoR-R129C variant. EpoR-R129C expression resulted in increased cellular proliferation and migration of breast cancer cells and these effects were associated with significantly increased Epo-induced phosphorylation of ERK1/2, AKT and c-Jun-NH2-kinase (SAPK/JNK) proteins. Expression of the constitutively active EpoR-R129C receptor promoted the proliferation and migration of breast cancer cells via activation of ERK- and SAPK/JNK-dependent signaling pathways, respectively. These findings suggest that EpoR over-expression and activation in breast cancer cells has the potential to contribute to tumor progression by promoting the proliferation and invasiveness of the neoplastic cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.